Head-to-head trial reveals better immune-dampening drug for psoriatic arthritis
A newer immune-dampening drug appears to effectively quell pain and swelling in joints affected by psoriatic arthritis, a new study says. The injectable drug bimekizumab (Bimzelx) eased psoriatic arthritis for more patients than a slightly older drug from its same class, risankizumab (Skyrizi), researchers reported at the American College of Rheumatology (ACR) conference in Orlando, Florida.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
